Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...

Country may have reached its peak for obesity levels, according to one of biggest online sellers of medications ...

Scheduled for 13 weeks, the trial will assess the therapy’s safety, tolerability, and efficacy in weight loss.

The initiation of the phase 2 study is based on early-stage data, which show that patients who received VKTX's obesity pill ...

STAT reporters discuss why a looming patent cliff could lead to more pharmaceutical deal-making and a new obesity startup.

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.

More than 500,000 people in the UK are now on the drugs and could lose between 15-20% of their weight in just a few months.

Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

HealthDay News — Racial and ethnic disparities are seen in the use of obesity-management medications, according to a study published online Dec. 17 in the Journal of Racial and Ethnic Health ...

"This tells us that it’s much more important, all things considered, to focus on the fitness aspect” of health and longevity, ...